Determining the Efficacy and Safety of Teneligliptin and Metformin Versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy | Chapter 6 | Technological Innovation in Pharmaceutical Research Vol. 10

 Type 2 diabetes mellitus is one of the most common non-communicable diseases, with both short- and long-term effects.

Material and Methods: The study included 60 patients, divided into two groups of 30 patients each. Teneligliptin 10 mg once a day and metformin 500 mg twice a day after meals were administered to Group 1 participants for 12 weeks. Glimepiride 1 mg once a day and metformin 500 mg twice a day after meals were administered to Group 2 patients for 12 weeks. Following the signed consent, the patient's medical history, clinical examination, and biochemical tests such as FBG, PPBG, HbA1c, and lipid profile were performed. FBG and PPBG were repeated every week for a total of 12 weeks. HbA1c and lipid profiles were measured at the start and end of the trial.

The change in FBG was greater in group 1 than in group 2. When comparing the drop in PPBG in patients in groups 1 and 2 there was a highly significant difference in group 1. HbA1c, total cholesterol, triglyceride levels, HDL, and LDL levels all changed more in group 1 than in group 2.

Conclusion: When compared to Glimepiride and metformin, teneligliptin and metformin resulted in a larger improvement in glycaemic and lipid profiles. Teneligliptin is therefore more effective than glimepiride.

Author (S) Details

Nitika Hans
Department of Pharmacology, Government Medical College, Amritsar, Punjab, India.

View Book :- https://stm.bookpi.org/TIPR-V10/article/view/2843